TrialChinese journal of cancer2011

Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.

Bing-He Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.